Clinical-Stage Biotechnology

Engineering the Future of Multi-Specific Antibodies

Discovering and developing innovative trispecific antibody therapeutics to transform treatment for patients with cancer and autoimmune diseases.

Explore Our Pipeline Our Technology
Chimagen Biosciences logo
Proprietary covalent multi-specific antibody platform — advancing a new generation of trispecific therapeutics.
2016
Founded
7+
Programs
$850M
GSK Deal
Global
Reach
Our Pipeline

Trispecific Therapeutics in the Clinic

A growing portfolio of novel multi-specific antibody programs targeting validated biology in oncology and autoimmune disease.

View full pipeline
Our Platform

A Proprietary Engine for Multi-Specific Innovation

Chimagen's covalent multi-specific antibody platform combines rational protein engineering with patented stabilization chemistry to create therapeutics that engage multiple disease targets simultaneously.

  • Trispecific formats with tunable target engagement
  • Enhanced stability and manufacturability
  • Protected by granted US patent 12,134,661 B1
Discover the platform
Chimagen platform
Latest News

Recent Announcements

All news

Partnering to Bring Breakthrough Therapies to Patients

We collaborate with global pharmaceutical companies and investors to accelerate the development of our multi-specific antibody pipeline.

Get in touch